Denali Therapeutics (DNLI) Earnings Forecast
What Wall Street expects this business to earn, and how much analysts disagree.
15 figures withheld by our checks. Each blank figure names its reason.
Analysts expect Denali Therapeutics to lose 1.75 a share in FY26 and 0.32 in FY30. 11 analysts publish an estimate for FY26 and 5 for FY30.
Are estimates going up or down lately?
The FY26 EPS consensus is −1.75, a loss that narrowed 27.2% in 91 days. Every figure compares one fiscal period at both ends.
EPS consensus, change over the last 91 days. One step per nightly change.
| EPS | 30 days | 90 daysshown above | Since Jul 6 |
|---|---|---|---|
| FY2611 analysts | ▲ +23.4%−2.29 to −1.75 | ▲ +27.2%−2.41 to −1.75 | ▲ +28.7%−2.46 to −1.75 |
| FY2713 analysts | ▲ +3.7%−2.35 to −2.26 | ▲ +7.4%−2.44 to −2.26 | ▲ +5.6%−2.39 to −2.26 |
| Sep '2611 analysts | ▲ +26.9%−0.37 to −0.27 | ▲ +54.5%−0.60 to −0.27 | ▲ +50.9%−0.55 to −0.27 |
| Dec '269 analysts | ▲ +3.3%−0.63 to −0.61 | ▲ +10.0%−0.67 to −0.61 | ▲ +10.0%−0.67 to −0.61 |
Contributors at both ends of the window: FY26 14 and 11. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.
Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.
If the Street is right, what does that imply for the share price?
The near-year consensus is −1.75 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.
We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.
Each point on the line is a multiple, and the flag is the price it implies for FY26. Past multiples are context, not a guide to future ones.
This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.
What you pay for the growth
Not computed across currencies. The consensus is in Denali Therapeutics' reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.
How much do analysts disagree?
For FY30, estimates run from −0.63 to −0.12 around an average of −0.32, drawn by 5 analysts.
A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.
Is next quarter a high bar or an easy one?
Analysts expect Denali Therapeutics to lose 0.61 a share in the December quarter, the average of 9 estimates. We hold no expected date for the next report.
For the March quarter, analysts expect a loss of 0.58 a share.
Does Denali Therapeutics usually beat or miss?
We have not been able to check a quarter yet. Our record of estimates for Denali Therapeutics begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.
We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.
Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Denali Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.
Where the growth comes from
The Street expects sales to grow 210.6% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.
Coverage, and the gap to the filing
11 analysts publish an EPS estimate for FY26 and 15 publish revenue. Coverage thins with distance: 5 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
The full consensus, year by year
Coverage thins with distance: 15 revenue estimates for FY26, 7 for FY30.
Out-year bands widen as fewer analysts publish: 11 EPS estimates for FY26, 5 for FY30.
| Fiscal year | Revenue reporting ccy B | YoY | EPS reporting ccy | YoY | EBITDA reporting ccy B | Net inc. reporting ccy B | Shares B | Analysts rev · EPS | Fwd P/E |
|---|---|---|---|---|---|---|---|---|---|
| FY25Filed · USD | — | — | −2.97 | — | — | — | — | as filed | n/m |
| FY26E | 0.10.0 to 0.1 | n/ca | −1.75−1.84 to −1.69 | n/ca | −0.3 | −0.3 | 0.18 | 15 · 11 | — |
| FY27E | 0.20.1 to 0.3 | ▲210.6% | −2.26−3.17 to −1.86 | — | −0.4 | −0.4 | 0.20 | 15 · 13 | — |
| FY28E | 0.30.1 to 0.5 | ▲95.2% | −1.71−2.41 to −0.77 | — | −0.4 | −0.4 | 0.22 | 15 · 13 | — |
| FY29E | 0.40.2 to 0.8 | ▲36.6% | −1.24−2.44 to −0.45 | — | −0.2 | −0.2 | 0.18 | 10 · 10 | — |
| FY30E | 0.70.3 to 1.2 | ▲55.6% | −0.32−0.63 to −0.12 | n/cb | −0.0 | −0.1 | 0.18 | 7 · 5 | — |
Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.
Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 11 EPS estimates for FY26, 15 for revenue. Not investment advice.

